other material
confidence high
sentiment positive
materiality 0.85
RAP-219 Phase 2a follow-up shows sustained seizure reduction; half-life updated to ~22 days
Rapport Therapeutics, Inc.
- 90% median reduction in clinical seizures in weeks 9-12; 59% in weeks 13-16, demonstrating sustained effect after treatment cessation.
- Updated half-life of ~22 days (prior 14 days) with plasma concentrations maintaining >75% receptor occupancy through week 12.
- Two Phase 3 FOS trials (FOCUS 1 & 2) expected to start Q2 2026; open-label extension ongoing with initial data H2 2026.
- RAP-219 well tolerated; 2 mild treatment-related AEs, 3 SAEs unrelated to drug. Phase 2 bipolar mania topline expected H1 2027.